ROLE OF ANTIOXIDANT VITAMIN E AND C ON PLATELET LEVELS IN DENGUE FEVER

*Prasanna Chandra¹, Hemant Sharma², Akash Gupta1¹ and Yogesh Rai¹

¹Department of Biochemistry, SIMS, Hapur, U.P. ²Department of Medicine, SIMS, Hapur, U.P.

ABSTRACT

The aim of the study was to assess the beneficial effects of vitamin E and C on thrombocytopenia in dengue patients. Blood samples of 48 suspected cases of dengue from medicine ward were collected. Serum antibodies (IgG, IgM) were detected by ELISA based readymade kits from J Mitra and company. Hemogram and complete blood count was also done. Only 27 fully diagnosed cases of dengue were given vitamin E and C supplementation according to prescribed limit for 8 days. Hb and platelet count was estimated on day 1 and Day 8. Data was analyzed by paired t test. In our study we found that mean Hb value was 10.2 ± 0.4 gm/dl on day 1 and it was 10.9 ± 0.3 gm/dl on day 8. Similarly mean platelet count was $1.8 \pm 0.3 \times 10^5$ on day 1 and $2.3 \pm 0.5 \times 10^5$ on day 8 that is after supplementation. Vitamin E and C supplementation may contribute to increase in platelet count and early recovery in dengue fever.

Key Words: Dengue fever, Dengue Hemorrhagic Fever, Thrombocytopenia, Vitamin E, Vitamin C.

INTRODUCTION

The word dengue is derived from the Swahili phrase Ka-dingo pepo meaning cramp like seizure. Dengue viruses (DV) belong to family Flaviviridae and there are four serotypes of the virus reffered to as DV-1. DV-2, DV-3 and DV-4. It is transmitted mainly by Aedes aegypti mosquito and also by Aedes albopictus. In India, the Aedes aegypti mosquitoes are primary vectors for DENV and CHIKV which are more prevalent in the low socio-economic conditions and high population density (Scott et al., 1997). All four serotypes can cause the full spectrum of disease from a subclinical infection to a mild self limiting disease, the Dengue fever (DF) and a severe disease that may be fatal, the dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS) (Nivedita et al., 2012). The first major wide spread epidemics DHS/DSS occurred in India in 1996 involving areas around Delhi and Lucknow and then it spread to all over the country (Dar et al., 1999; Agarwal et al., 1999; Shah et al., 2008). In Delhi till 2003 the predominant serotype was DV-2 (genotype IV) but in 2003 for the first time all four Dengue virus subtypes were found to co-circulate in Delhi thus changing it to a hyperendemic state followed by complete predominance of DV serotype 3 in 2005 (Dar et al., 1999; Gupta et al., 2006). The classical clinical presentation of Dengue virus infection includes fever, joint pains, headaches and rashes (petechial or maculopaular rash) usually involving the limbs and trunks are the characteristic symptoms of the disease. In addition, thrombocytopenia is more marked and develops earlier in cases with a fatal outcome (Fausi et al., 2008). However many other types of clinical presentations have been observed. They are neurological, hepatic, cutaneous and gastrointestinal. Among neurological manifestation encephalopathy, acute motor weakness, seizures, neuritis, hypokalemic paralysis are common (Misra et al., 2006; Verma et al., 2012; Kumar et al., 2008; Verma et al., 2011). In the hepatic involvement acute liver failure, hepatic encephalopathy, hepatomegaly and jaundice are commonly seen (Deepak et al., 2006; Vinodh et al., 2005; Giri et al., 2008; Jhamb et al., 2011). In the gastrointestinal (GI) system lower GI bleeding and acute inflammatory colitis are seen (Rama et al., 2006). Hemophagolytic syndrome includes bone marrow heamophagocytosis associcated with nasal bleeding and pancytopenia (Jain et al., 2008; Ray et al., 2011; Kapdi et al., 2012). Cytotoxic factor (CF), a unique cytokine, is produced by CD4+ T cells in DV infected mice and man. Most of the patients with Dengue virus infection have CF in their sera, with peak amounts in the most severe cases of DHF (Mukarjee et al., 1997; Chaturvedi et al., 1999). CF appears in the serum before the clinical illness and is present in 100 percent patients with DF/DHF up to day 4 of illness,

Research Article

detectable up to 20 days of illness (Chadurvedi *et al.*, 2006). Macrophages are the primary component of the host innate immune system and provide first line of defence against viral infections. But in Dengue viral infection, the macrophages play multiple paradoxical roles, sometimes these help in eradicating the virus, while sometimes these actually increase its replication within the host (Chaturvedi *et al.*, 2006). CF-2 is a biological active protein and causes various immunopathological effects including increased vascular permeability and damage to the blood brain barrier (Khanna *et al.*, 1990; Dhawan et al. 1990; Chaturvedi *et al.*, 1986; Chaturvedi *et al.*, 1989) DV-2 inhibits in vitro megakaryopoiesis and induces apoptotic cell death in subpopulation of early megakaryocytic progenitors which may contribute to thrombocytopenia in dengue disease (Basu *et al.*, 2008). In another study it was shown that DV-2 may directly interact with and activate platelets and thus may be responsible for thrombocytopenia (Ghosh *et al.*, 2008). Oxidative stress develops from the onset of Dengue infection. Increase in oxidative stress significantly elevates plasma protein carbonyl and lower the protein bound sulfhydryl group. This ratio is reported to cause DHF/DSS (Soundravally *et al.*, 2008; Soundravally *et al.*, 2008).

MATERIALS AND METHODS

The study was conducted in Saraswathi Institute of Medical Sciences in the Department of Medicine in collaboration with Biochemistry, after obtaining ethical clearance from the institutional ethical committee. Patients were recruited for the study after taking their due written consent. Blood samples of 48 suspected Dengue cases from medicine wards were collected during a period from October 2012 to December 2012. Sera were separated for antidengue IgM and IgG antibody, which were tested by ELISA kits from J Mitra and Co in the Microbiology Department. Hemogram including platelet count and complete blood was Pathology department. count done in Out of 48 patients only 27 were included in our study (17 males and 10 females) and all of these were having platelet count within normal reference range $(1.5 - 4 \times 10^5 / \text{ cu mm})$. These 27 patients were given Vitamin E and C in the prescribed limit. 400 mg of Vit E (Cap Evion) was given once daily for 8 days and 500mg of Vit C (Tab Celin) was given thrice a day for 8 days. After initiating Vit E and Vit C supplementation there platelet count were measured first on Day 1 and again on Day 8. The remaining 21 patient were excluded from the study. The exclusion criteria were h/o bleeding disorder, severe thrombocytopenia requiring platelet transfusion, severe anemia and seriously ill patients. Finally Data was analyzed by paired t test.

RESULTS AND DISCUSSION

Present study involves the role of Vit E and C on platelets in Dengue Fever. In our study we found that mean Hb value was 10.2 ± 0.4 gm/dl at Day 1 and it was 10.9 ± 0.3 gm/dl at Day 8. Similarly mean platelet count was $1.8 \pm 0.3 \times 10^5$ at Day 1 and $2.3 \pm 0.5 \times 10^5$ at Day 8. It was found that mean platelet count was increased significantly by Vit E and Vit C supplementation (*P* value < 0.01) in Dengue patients (Table 1):

(Day 1	Day 8	P value
Mean Hb	$10.2 \pm 0.4 \text{ gm/dl}$	$10.9\pm0.3~gm/dl$	<i>P</i> < 0.01
Mean platelet count	$1.8\pm0.3\times10^{5}\!/\ cu\ mm$	$2.3\pm0.5\times10^{5}\!/$ cu mm	<i>P</i> < 0.01

Dengue infection is no more an urban area infection but it has penetrated in rural areas also (Nivedita *et al.*, 2012). The management of Dengue virus infection is essentially supportive and symptomatic. No specific treatment is available. However, there are Indian studies which have contributed in terms of better management of DHF/DSS. The pathogenesis of thrombocytopenia in Dengue fever is not clear but increased oxidative stress may have a role (Gil *et al.*, 2004; Klassen *et al.*, 2004). A rapid response to platelet and fresh frozen plasma transfusion is reported a study (Choudhry *et al.*, 2006). The role of

Research Article

platelet transfusion in the management of hospitalized Dengue patients may vary for indication and situations. Vitamin E which has antioxidant and free radical scavenging properties, may therefore help in these cases (Sies *et al.*, 1995; Mascio *et al.*, 1991). Similarly Vaish et al observed that supplementation of antioxidant Vitamin E increased the count in dengue patients and they also concluded that Vitamin E can accelerate replenishment of the circulation with platelets in dengue fever, thereby reducing the risk of bleeding (Arvind *et al.*, 2012).

Vitamin E and C stimulate immune system function in supplementation studies (Hennekens, 1994). CF/CF2 induces macrophages to produce free radicals, nitrite, reactive oxygen and peroxynitrite (Misra *et al.*, 1996; Misra *et al.*, 1996; Chaturvedi *et al.*, 2006; Chaturvedi *et al.*, 2000; Misra *et al.*, 1998; Chaturvedi *et al.*, 1997).The free radicals, beside killing the target cells by apoptosis also directly up regulate production of pro-inflammatory cytokines; interleukin (IL-1), tumor necrosis factor (TNF- α), IL-8 and hydrogen peroxide in macrophage (Nivedita *et al.*, 2012). Bleeding manifestation is highly variable and do not always correlate with the laboratory abnormalities in the coagulation profile. Factors like mild degree of disseminated intravascular coagulation (DIC), hepatic derangement and thrombocytopenia act synergistically to cause bleeding in dengue patient (Shivbalan *et al.*, 2004). Severe bleeding is related to severe thrombocytopenia (Chairulfatah *et al.*, 2003). Reduced levels of plasma ascorbate and tocopherol may contribute to oxidative destruction of thrombocytes. So from our study we come to conlusion that administration of antioxidant Vitamin E and C along with the treatment may be fruitful to avoid thrombocytopenia in dengue patients.

Conclusion

Vitamin E and C supplementation may contribute to increase in platelet count and early recovery in dengue fever.

REFERENCES

Scott TW, Naksathit A, Day JF, Kittayapong P, Edman JD (1997). A fitness advantage for Aedes aegypti and the viruses it transmits when females feed only on human blood. *American Journal of Tropical Medicine and Hygiene* 57 235-239.

Nivedita Gupta, Sakshi Srivastava, Amita Jain, Umesh C Chaturvedi (2012). Dengue in India CENTENARY REVIEW ARTICLE. *Indian Journal of Medical Research* **136**(3) 373-390

Dar L, Broor S, Sengupta S, Xess I, Seth P (1999). The first major outbreak of dengue hemorrhagic fever in Delhi, India. *Journal of Emergency Infectitious Diseases* 5 589-590.

Agarwal R, Kapoor S, Nagar R, Misra A, Tandon R, Mathur A (1999). A clinical study of the patients with dengue hemorrhagic fever during the epidemic of 1996 at Lucknow, India. *Southeast Asian Journal of Tropical Medicine Public Health* **30** 735-740.

Shah I, Deshpande GC, Tardeja PN (2004). Outbreak of dengue in Mumbai and predictive markers for dengue shock syndrome. *Journal of Tropical Pediatrics* **50** 301-305

Dar L, Broor S, Sengupta S, Xess I, Seth P (1999). The first major outbreak of dengue hemorrhagic fever in Delhi, India. *Journal of Emergency Infectitious Diseases* 5 589-590

Gupta E, Dar L, Kapoor G, Broor S (2006). The changing epidemiology of dengue in Delhi, India. *Journal of Medical Virology* **3** 92-96.

Fauci AS, Braunwald, Eugene, Kasper, Dennis L, Hauser, Stephen L (2008). Harrison's Principle of Internal Medicine, Mc Graw Hill 17 1234-1237.

Misra UK, Kalita J, Syam UK, Dhole TN (2006). Neurological manifestations of dengue virus infection. *Journal of NeuroScience* 244 117-122.

Verma R, Sharma P, Garg RK, Atam V, Singh MK, Mehrotra HS (2011). Neurological complications of dengue fever: Experience from a tertiary center of north India. *Annals of Indian Academy of Neurology* 14 272-278.

Research Article

Kumar R, Tripathi S, Tambe JJ, Arora V, Srivastava A, Nag VL (2008). Dengue encephalopathy in children in Northern India: clinical features and comparison with non dengue. *Journal of NeuroScience* 269 41-48

Verma R, Varatharaj A (2011). Epilepsia partialis continua as a manifestation of dengue encephalitis. *Epilepsy Behav*iour 20 395-397.

Deepak NA, Patel ND (2006). Differential diagnosis of acute liver failure in India. *Annals of Hepatology* **5** 150-156.

Vinodh BN, Bammigatti C, Kumar A, Mittal V (2005). Dengue fever with acute liver failure. *Journal* of Postgraduate Medicine 51 322-323

Giri S, Agarwal MP, Sharma V, Singh A (2008). Acute hepatic failure due to dengue: A case report. *Cases Journal* 1 204-210

Jhamb R, Kashyap B, Ranga GS, Kumar A (2011). Dengue fever presenting as acute liver failure - a case report. *Asian Pacific Journal of Tropical Medicine* **4** 323-324.

Rama Krishna AK, Patil S, Srinivas Rao G, Kumar A (2006). Dengue fever presenting with acute colitis. *Indian Journal of Gastroenterology* 25 97-98

Jain D, Singh T (2008). Dengue virus related hemophagocytosis: a rare case report. *Hematology* 13 286-288.

Ray S, Kundu S, Saha M, Chakrabarti P (2011). Hemophagocytic syndrome in classic dengue fever. *Journal of Global Infectitious Diseases* **3** 399-401.

Kapdi M, Shah I (2012). Dengue and haemophagocytic lymphohistiocytosis. *Scandinavian Journal of Infectious Diseases* 44 708-709.

Mukerjee R, Chaturvedi UC, Vaughn DW, Kalayanarooj S (1997). Purification and pathogenicity of the cytotoxic factor from the cases of dengue haemorrhagic fever. *Journal of Current State of Science* **72** 494-501.

Chaturvedi UC, Elbishbishi EA, Agarwal R, Raghupathy R, Nagar R, Tandon R, (1999). Sequential production of cytokines by dengue virus-infected human peripheral blood leukocyte cultures. *Journal of Medical Virology* **59** 335-340.

Chaturvedi UC, Nagar R, Shrivastava R (2006). Macrophage & dengue virus: Friend or foe? *Indian Journal of Medical Research* 124 23-40.

Khanna M, Chaturvedi UC, Sharma MC, Pandey VC, Mathur A (1990). Increased capillary permeability mediated by a dengue virus-induced lymphokine. *Journal of Immunology* **69** 449-54.

Dhawan R, Khanna M, Chaturvedi UC, Mathur A (1990). Effect of dengue virus-induced cytotoxin on capillary permeability. *British Journal of Experimental Pathology* 71 83-88.

Chaturvedi UC (1986). Virus-induced cytotoxic factor in AIDS and dengue. *Journal of Immunology Today*. **7** 159.

Chaturvedi UC (1989). Togavirus-induced immunosuppression. In: Specter S, Bendinelli M, Friedman H, *Virus-induced immunosuppression*. New York: Plenum Press 253-283.

Basu A, Jain P, Gangodkar S, Shetty S, Ghosh K (2008). Dengue 2 virus inhibits *in vitro* megakaryocytic colony formation and induce apoptosis in thrombopoietin-inducible megakaryocytic differentiation from cord blood CD34+ cells. *FEMS Journal of Immunology and Medical Microbiology* **53** 46-51.

Ghosh K, Gangodkar S, Jain P, Shetty S, Ramjee S, Poddar P (2008). Imaging the interaction between dengue 2 virus and human blood platelets using atomic force and electron microscopy *Journal of Electron Microscopy* 57 113-118.

Soundravally R, Sankar P, Bobby Z, Hoti SL (2008). Oxidative stress in severe dengue viral infection: association of thrombocytopenia with lipid peroxidation. *Platelets*.19 447-454.

Soundravally R, Sankar P, Hoti SL, Selvaraj N, Bobby Z, Sridhar MG (2008). Oxidative stress induced changes in plasma protein can be a predictor of imminent severe dengue infection. *Journal Acta Tropica* **106** 156-161.

Research Article

Gil L, Martínez G, Tápanes R, Castro O, González D, Bernardo L (2004). Oxidative stress in adult dengue patients. *American Journal of Tropical Medicineand Hygiene* **71** 652-657

Klassen P, Biesalski HK, Mazariegos M, Solomons NW, Fürst P (2004). Classic Dengue fever affects levels of circulating antioxidants. *Journal of Nutrition* 20 542-547

Chaudhary R, Khetan D, Sinha S, Sinha P, Sonker A, Pandey P (2006). Transfusion support to Dengue patients in a hospital based blood transfusion service in north India. *Transfusion and Apheresis Science* 35 239-244

Sies H, Stahl W (1995). Vitamins E and C, beta-carotene, and other carotenoids as antioxidants. *American Journal of Clinical Nutrition* 62 1315S-21.

Mascio PD, Murphy ME, Sies H (1991). Antioxidant defense systems: the role of carotenoids, tocopherols, and thiols. *American Journal of Clinical Nutrition* 53 194S-200.

Arvind Vaish, Sudhir Verma, Abhishek Agarwal, Lokesh Gupta, Manish Gutch (2012). Effect of vitamin E on thrombocytopenia in dengue fever. *Annals of Tropical Medicine and Public Health* 5(4) 282-285

Hennekens CH (1994). Antioxidant vitamins and cancer. American Journal of Medicine 97(suppl) 22S-28S

Misra A, Mukerjee R, Chaturvedi UC (1996). Production of nitrite by dengue virus-induced cytotoxic factor. *Journal of Clinical and Experimental Immunology* 104 406-411.

Misra A, Mukerjee R, Chaturvedi UC (1996). Release of reactive oxygen intermediates by dengue virus-induced macrophage cytotoxin. *International Journal of Experimental Pathology* **77** 237-242.

Chaturvedi UC, Nagar R, Shrivastava R (2006). Macrophage & dengue virus: Friend or foe? Indian Journal of Medical Research 24 23-40 Chaturvedi UC, Agarwal R, Elbishbishi EA, Mustafa AS (2000). Cytokine cascade in dengue haemorrhagic fever: Implications for pathogenesis. FEMS Jounal of Immunologyand Medical Microbiology 28 183-188.

Misra A, Mukerjee R, Chaturvedi UC (1998). Respiratory burst by dengue virus-induced cytotoxic factor. *Journal of Medical Principles and Pracice* 7 251-260.

Chaturvedi UC, Dhawan R, Mukerjee R (1997). Immunosuppression and cytotoxicity of dengue infection in the mouse model. In: Gubler DJ, Kuno G, editors. *Dengue and dengue haemorrhagic fever*. Wallingford, Oxon, U.K.: CAB International Press 291-312.

Shivbalan S, Anandnathan K, Balasubramanian S, Datta M, Amalraj E (2004). Predictors of spontaneous bleeding in Dengue. *Indian Journal of Pediatrics* **71** 33-36.

Chairulfatah A, Setiabudi D, Agoes R, Colebunder R (2003). Thrombocytopenia and platelet transfusions in dengue Haemorrhagic Fever and Dengue Shock Syndrome. *WHO Dengue* Bulletin 27 141-143.